treatment of myasthenia gravis
Conditions
Interventions
None listed
Sponsors
Vianex S.A.
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Outcome results
None listed
An open label, randomized, multiple-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fasting conditions.
For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms
Source: EU CTIS · Data processed: Jun 3, 2026